English
简体中文
Total: £ 56.28
Published Date: 2026-04-02 | Pages: 115 | Tables: 110 | Pharma & Healthcare
The global Nanomaterial-Based Adjuvants Vaccine market was valued at US$ 355310 million in 2025 and is anticipated to reach US$ 670310 million by 2032, at a CAGR of 9.6% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Nanomaterial-Based Adjuvants Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Nanoparticles (NPs) can act as adjuvants for vaccines, hence they are referred to as a nano-adjuvant (NA). NPs can either encapsulate or adsorb the vaccine antigen or DNA in an appropriate formulation, thus increasing stability, cellular uptake, and immunogenicity.
Global key players of Nanomaterial-Based Adjuvants Vaccine include Emergent BioSolutions, Sanofi, etc. Global top 3 companies hold a share over 80%. North America is the largest market, with a share about 60%, followed by Europe and Japan with the share about 20% and 5%. In terms of product, Lipidosome is the largest segment, with a share about 80%. And in terms of application, the largest application is SARS-CoV-2, with a share about 75%.
Technological advancements in nanomaterial-based adjuvants vaccines are an important factor driving market development. Nano-adjuvants have the advantages of good biocompatibility, biological targeting, sustained release, safety and high efficiency, and can significantly improve the immunogenicity and protective effect of vaccines. With the continuous development and application of nanotechnology, the types and performance of nanomaterial-based adjuvants vaccines will be further improved to meet the needs of more disease prevention. As the market continues to expand and potential competitors join, competition in the nanomaterial-based adjuvants vaccines market will become more intense. Overall, the nanomaterial-based adjuvants vaccines market has broad prospects. With the advancement of technology and the increase in market demand, the market size is expected to continue to grow in the next few years.
This report delivers a comprehensive overview of the global Nanomaterial-Based Adjuvants Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Nanomaterial-Based Adjuvants Vaccine. The Nanomaterial-Based Adjuvants Vaccine market size, estimates, and forecasts are provided in terms of sales volume (M Doses) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Nanomaterial-Based Adjuvants Vaccine market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Nanomaterial-Based Adjuvants Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Emergent BioSolutions
Sanofi
GlaxoSmithKline Biologicals
Merck
Pfizer
Novartis
Moderna
Jiangsu Recbio Technology
Segment by Type
Aluminium Hydroxides
Aluminium Phosphate
Lipidosome
Others
by Application
Pneumococcus
Human Papilloma Virus
DTaP
Viral Hepatitis TypeA
Viral Hepatitis TypeB
SARS-CoV-2
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Nanomaterial-Based Adjuvants Vaccine manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Nanomaterial-Based Adjuvants Vaccine sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Nanomaterial-Based Adjuvants Vaccine Market Overview
1.1 Product Definition
1.2 Nanomaterial-Based Adjuvants Vaccine by Type
1.2.1 Global Nanomaterial-Based Adjuvants Vaccine Market Value by Type: 2025 vs 2032
1.2.2 Aluminium Hydroxides
1.2.3 Aluminium Phosphate
1.2.4 Lipidosome
1.2.5 Others
1.3 Nanomaterial-Based Adjuvants Vaccine by Application
1.3.1 Global Nanomaterial-Based Adjuvants Vaccine Market Value by Application: 2025 vs 2032
1.3.2 Pneumococcus
1.3.3 Human Papilloma Virus
1.3.4 DTaP
1.3.5 Viral Hepatitis TypeA
1.3.6 Viral Hepatitis TypeB
1.3.7 SARS-CoV-2
1.3.8 Others
1.4 Global Nanomaterial-Based Adjuvants Vaccine Market Size Estimates and Forecasts
1.4.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue 2021–2032
1.4.2 Global Nanomaterial-Based Adjuvants Vaccine Sales 2021–2032
1.4.3 Global Nanomaterial-Based Adjuvants Vaccine Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Nanomaterial-Based Adjuvants Vaccine Market Competition by Manufacturers
2.1 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Manufacturers (2021–2026)
2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Nanomaterial-Based Adjuvants Vaccine Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Nanomaterial-Based Adjuvants Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Product Types and Applications
2.7 Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Date of Entry into the Industry
2.8 Global Nanomaterial-Based Adjuvants Vaccine Market Competitive Situation and Trends
2.8.1 Global Nanomaterial-Based Adjuvants Vaccine Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Nanomaterial-Based Adjuvants Vaccine Players Market Share by Revenue
2.8.3 Global Nanomaterial-Based Adjuvants Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Nanomaterial-Based Adjuvants Vaccine Market Scenario by Region
3.1 Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region: 2021–2032
3.2.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region: 2021–2026
3.2.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region: 2027–2032
3.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2021–2032
3.3.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2021–2026
3.3.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2027–2032
3.4 North America Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country
3.4.1 North America Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021–2032)
3.4.3 North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country
3.5.1 Europe Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021–2032)
3.5.3 Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (2021–2032)
3.6.3 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country
3.7.1 Latin America Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021–2032)
3.7.3 Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021–2032)
3.8.3 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2021–2032)
4.1.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2021–2026)
4.1.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2027–2032)
4.1.3 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2021–2032)
4.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2021–2032)
4.2.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2021–2026)
4.2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2027–2032)
4.2.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2021–2032)
4.3 Global Nanomaterial-Based Adjuvants Vaccine Price by Type (2021–2032)
5 Segment by Application
5.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2021–2032)
5.1.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2021–2026)
5.1.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2027–2032)
5.1.3 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2021–2032)
5.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2021–2032)
5.2.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2021–2026)
5.2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2027–2032)
5.2.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2021–2032)
5.3 Global Nanomaterial-Based Adjuvants Vaccine Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Emergent BioSolutions
6.1.1 Emergent BioSolutions Company Information
6.1.2 Emergent BioSolutions Description and Business Overview
6.1.3 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.1.5 Emergent BioSolutions Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Company Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Sanofi Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 GlaxoSmithKline Biologicals
6.3.1 GlaxoSmithKline Biologicals Company Information
6.3.2 GlaxoSmithKline Biologicals Description and Business Overview
6.3.3 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.3.5 GlaxoSmithKline Biologicals Recent Developments/Updates
6.4 Merck
6.4.1 Merck Company Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Merck Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Company Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Pfizer Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Company Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Novartis Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 Moderna
6.7.1 Moderna Company Information
6.7.2 Moderna Description and Business Overview
6.7.3 Moderna Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Moderna Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.7.5 Moderna Recent Developments/Updates
6.8 Jiangsu Recbio Technology
6.8.1 Jiangsu Recbio Technology Company Information
6.8.2 Jiangsu Recbio Technology Description and Business Overview
6.8.3 Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.8.5 Jiangsu Recbio Technology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Nanomaterial-Based Adjuvants Vaccine Industry Chain Analysis
7.2 Nanomaterial-Based Adjuvants Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nanomaterial-Based Adjuvants Vaccine Production Mode & Process Analysis
7.4 Nanomaterial-Based Adjuvants Vaccine Sales and Marketing
7.4.1 Nanomaterial-Based Adjuvants Vaccine Sales Channels
7.4.2 Nanomaterial-Based Adjuvants Vaccine Distributors
7.5 Nanomaterial-Based Adjuvants Vaccine Customer Analysis
8 Nanomaterial-Based Adjuvants Vaccine Market Dynamics
8.1 Nanomaterial-Based Adjuvants Vaccine Industry Trends
8.2 Nanomaterial-Based Adjuvants Vaccine Market Drivers
8.3 Nanomaterial-Based Adjuvants Vaccine Market Challenges
8.4 Nanomaterial-Based Adjuvants Vaccine Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Nanomaterial-Based Adjuvants Vaccine Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Nanomaterial-Based Adjuvants Vaccine Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Nanomaterial-Based Adjuvants Vaccine Market Competitive Situation by Manufacturers in 2025
Table 4. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) of Key Manufacturers (2021–2026)
Table 5. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Nanomaterial-Based Adjuvants Vaccine Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Nanomaterial-Based Adjuvants Vaccine Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Nanomaterial-Based Adjuvants Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Product Types and Applications
Table 12. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Nanomaterial-Based Adjuvants Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on Nanomaterial-Based Adjuvants Vaccine Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (M Doses), 2021–2026
Table 18. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2021–2026)
Table 19. Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (M Doses), 2027–2032
Table 20. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2027–2032)
Table 21. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (US$ Million), 2021–2026
Table 22. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2021–2026)
Table 23. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (US$ Million), 2027–2032
Table 24. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2027–2032)
Table 25. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2021–2026
Table 27. North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2027–2032
Table 28. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2021–2026
Table 29. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2021–2026
Table 32. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2027–2032
Table 33. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (M Doses), 2021–2026
Table 37. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (M Doses), 2027–2032
Table 38. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2021–2026
Table 42. Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2027–2032
Table 43. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2021–2026
Table 47. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2027–2032
Table 48. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2027–2032
Table 50. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Type (2021–2026)
Table 51. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Type (2027–2032)
Table 52. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2021–2026)
Table 53. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2027–2032)
Table 54. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2021–2026)
Table 57. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2027–2032)
Table 58. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2021–2026)
Table 59. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2027–2032)
Table 60. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Application (2021–2026)
Table 61. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Application (2027–2032)
Table 62. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2021–2026)
Table 63. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2027–2032)
Table 64. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2021–2026)
Table 67. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2027–2032)
Table 68. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2021–2026)
Table 69. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2027–2032)
Table 70. Emergent BioSolutions Company Information
Table 71. Emergent BioSolutions Description and Business Overview
Table 72. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product
Table 74. Emergent BioSolutions Recent Developments/Updates
Table 75. Sanofi Company Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Sanofi Nanomaterial-Based Adjuvants Vaccine Product
Table 79. Sanofi Recent Developments/Updates
Table 80. GlaxoSmithKline Biologicals Company Information
Table 81. GlaxoSmithKline Biologicals Description and Business Overview
Table 82. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product
Table 84. GlaxoSmithKline Biologicals Recent Developments/Updates
Table 85. Merck Company Information
Table 86. Merck Description and Business Overview
Table 87. Merck Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Merck Nanomaterial-Based Adjuvants Vaccine Product
Table 89. Merck Recent Developments/Updates
Table 90. Pfizer Company Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 93. Pfizer Nanomaterial-Based Adjuvants Vaccine Product
Table 94. Pfizer Recent Developments/Updates
Table 95. Novartis Company Information
Table 96. Novartis Description and Business Overview
Table 97. Novartis Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 98. Novartis Nanomaterial-Based Adjuvants Vaccine Product
Table 99. Novartis Recent Developments/Updates
Table 100. Moderna Company Information
Table 101. Moderna Description and Business Overview
Table 102. Moderna Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 103. Moderna Nanomaterial-Based Adjuvants Vaccine Product
Table 104. Moderna Recent Developments/Updates
Table 105. Jiangsu Recbio Technology Company Information
Table 106. Jiangsu Recbio Technology Description and Business Overview
Table 107. Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 108. Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Product
Table 109. Jiangsu Recbio Technology Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Nanomaterial-Based Adjuvants Vaccine Distributors List
Table 113. Nanomaterial-Based Adjuvants Vaccine Customers List
Table 114. Nanomaterial-Based Adjuvants Vaccine Market Trends
Table 115. Nanomaterial-Based Adjuvants Vaccine Market Drivers
Table 116. Nanomaterial-Based Adjuvants Vaccine Market Challenges
Table 117. Nanomaterial-Based Adjuvants Vaccine Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 121. Authors List of This Report
List of Figures
Figure 1. Product Picture of Nanomaterial-Based Adjuvants Vaccine
Figure 2. Global Nanomaterial-Based Adjuvants Vaccine Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Nanomaterial-Based Adjuvants Vaccine Market Share by Type: 2025 & 2032
Figure 4. Aluminium Hydroxides Product Picture
Figure 5. Aluminium Phosphate Product Picture
Figure 6. Lipidosome Product Picture
Figure 7. Others Product Picture
Figure 8. Global Nanomaterial-Based Adjuvants Vaccine Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Nanomaterial-Based Adjuvants Vaccine Market Share by Application: 2025 & 2032
Figure 10. Pneumococcus
Figure 11. Human Papilloma Virus
Figure 12. DTaP
Figure 13. Viral Hepatitis TypeA
Figure 14. Viral Hepatitis TypeB
Figure 15. SARS-CoV-2
Figure 16. Others
Figure 17. Global Nanomaterial-Based Adjuvants Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 18. Global Nanomaterial-Based Adjuvants Vaccine Market Size (US$ Million), 2021–2032
Figure 19. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), 2021–2032
Figure 20. Global Nanomaterial-Based Adjuvants Vaccine Average Price (US$/Dose), 2021–2032
Figure 21. Nanomaterial-Based Adjuvants Vaccine Report Years Considered
Figure 22. Nanomaterial-Based Adjuvants Vaccine Sales Share by Manufacturers in 2025
Figure 23. Global Nanomaterial-Based Adjuvants Vaccine Revenue Share by Manufacturers in 2025
Figure 24. Top 5 and Top 10 Global Nanomaterial-Based Adjuvants Vaccine Players: Market Share by Revenue in Nanomaterial-Based Adjuvants Vaccine in 2025
Figure 25. Nanomaterial-Based Adjuvants Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 26. Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 27. North America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021–2032)
Figure 28. North America Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2021–2032)
Figure 29. United States Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Canada Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Europe Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021–2032)
Figure 32. Europe Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2021–2032)
Figure 33. Germany Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. France Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. U.K. Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Italy Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Russia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2021–2032)
Figure 39. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2021–2032)
Figure 40. China Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Japan Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. South Korea Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. India Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Australia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. China Taiwan Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Indonesia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Thailand Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Malaysia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Latin America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021–2032)
Figure 50. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2021–2032)
Figure 51. Mexico Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Brazil Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Argentina Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021–2032)
Figure 55. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2021–2032)
Figure 56. Turkey Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Saudi Arabia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. UAE Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. Global Sales Market Share of Nanomaterial-Based Adjuvants Vaccine by Type (2021–2032)
Figure 60. Global Revenue Market Share of Nanomaterial-Based Adjuvants Vaccine by Type (2021–2032)
Figure 61. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2021–2032)
Figure 62. Global Sales Market Share of Nanomaterial-Based Adjuvants Vaccine by Application (2021–2032)
Figure 63. Global Revenue Market Share of Nanomaterial-Based Adjuvants Vaccine by Application (2021–2032)
Figure 64. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2021–2032)
Figure 65. Nanomaterial-Based Adjuvants Vaccine Value Chain
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
